Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Microba Life Sciences Limited ( (AU:MAP) ) is now available.
Microba Life Sciences Limited held its Annual General Meeting, where all proposed resolutions were passed, except for the re-election of Dr. Hyungtae Kim, who retired. Notably, the approval of a 10% Placement Facility was achieved, which could enhance the company’s financial flexibility and strategic positioning.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited is a leader in microbiome health and human care, offering clinical-grade microbiome tests aimed at improving health outcomes. The company leverages advanced science and collaboration tools to provide insights that promote healthier living.
Average Trading Volume: 677,689
Technical Sentiment Signal: Sell
Current Market Cap: A$44.45M
For detailed information about MAP stock, go to TipRanks’ Stock Analysis page.